Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company focused on molecular glue degrader (MGD)-based medicines, has announced its participation in two upcoming investor conferences. The company will attend the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, in New York. Additionally, CEO Markus Warmuth will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025, at 9:00 a.m. ET. The fireside chat will be available via webcast on the company's investor relations website.
Monte Rosa Therapeutics (Nasdaq: GLUE), società biofarmaceutica in fase clinica focalizzata su farmaci basati su molecular glue degrader (MGD), ha annunciato la sua partecipazione a due prossimi convegni per investitori. La società sarà presente al Morgan Stanley 23rd Annual Global Healthcare Conference l'8 settembre 2025 a New York. Inoltre, l'amministratore delegato Markus Warmuth prenderà parte a una fireside chat al Stifel 2025 Virtual Immunology and Inflammation Forum il 15 settembre 2025 alle 9:00 ET. La fireside chat sarà trasmessa in webcast sul sito web per gli investitori della società.
Monte Rosa Therapeutics (Nasdaq: GLUE), una biotecnológica en fase clínica centrada en fármacos basados en molecular glue degrader (MGD), ha anunciado su participación en dos próximas conferencias para inversores. La compañía asistirá al Morgan Stanley 23rd Annual Global Healthcare Conference el 8 de septiembre de 2025 en Nueva York. Además, el CEO Markus Warmuth participará en una charla informal en el Stifel 2025 Virtual Immunology and Inflammation Forum el 15 de septiembre de 2025 a las 9:00 a.m. ET. La charla se podrá seguir por webcast en la web de relaciones con inversores de la compañía.
Monte Rosa Therapeutics (Nasdaq: GLUE)는 molecular glue degrader(MGD) 기반 의약품을 개발하는 임상 단계의 바이오텍으로, 다가오는 두 건의 투자자 컨퍼런스에 참가한다고 발표했습니다. 회사는 2025년 9월 8일 뉴욕에서 열리는 Morgan Stanley 23rd Annual Global Healthcare Conference에 참석합니다. 또한 최고경영자 Markus Warmuth는 2025년 9월 15일 오전 9시(동부시간)에 열리는 Stifel 2025 Virtual Immunology and Inflammation Forum의 파이어사이드 채트에 참여합니다. 이 파이어사이드 채트는 회사 투자자 관계 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
Monte Rosa Therapeutics (Nasdaq: GLUE), une société biotechnologique en phase clinique spécialisée dans les médicaments basés sur les molecular glue degrader (MGD), a annoncé sa participation à deux prochaines conférences pour investisseurs. La société assistera au Morgan Stanley 23rd Annual Global Healthcare Conference le 8 septembre 2025 à New York. De plus, le PDG Markus Warmuth participera à une discussion informelle lors du Stifel 2025 Virtual Immunology and Inflammation Forum le 15 septembre 2025 à 9h00 ET. La discussion sera diffusée en webcast sur le site relations investisseurs de la société.
Monte Rosa Therapeutics (Nasdaq: GLUE), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf molecular glue degrader (MGD)-basierte Therapeutika konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird am Morgan Stanley 23rd Annual Global Healthcare Conference am 8. September 2025 in New York teilnehmen. Zudem wird CEO Markus Warmuth am Stifel 2025 Virtual Immunology and Inflammation Forum am 15. September 2025 um 9:00 Uhr ET an einem Fireside-Chat teilnehmen. Der Fireside-Chat wird per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
- Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY) – September 8, 2025.
- Stifel 2025 Virtual Immunology and Inflammation Forum – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 15, 2025, at 9:00 a.m. ET.
A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When is Monte Rosa Therapeutics (GLUE) presenting at the Morgan Stanley Healthcare Conference 2025?
What time is Monte Rosa's (GLUE) presentation at the Stifel 2025 Virtual Immunology Forum?
Where can I watch Monte Rosa Therapeutics' (GLUE) Stifel conference presentation?
What type of medicines is Monte Rosa Therapeutics (GLUE) developing?
